Humacyte (HUMA) Amortizatization of Intangibles (2021 - 2026)
Humacyte (HUMA) posted quarterly Amortizatization of Intangibles of $282000.0 for Q1 2026, down 46.18% year-over-year from $524000.0 in Q1 2025, and down 36.91% quarter-over-quarter from $447000.0 in Q4 2025.
Humacyte (HUMA) Amortizatization of Intangibles (2021 - 2026) Analysis & Trends
Humacyte (HUMA) has reported Amortizatization of Intangibles for 6 consecutive years, with $282000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Amortizatization of Intangibles fell 46.18% year-over-year to $282000.0; the TTM figure through Mar 2026 stood at $1.8 million (down 15.11% YoY), while the FY2025 annual figure was $2.0 million, down 3.31% from the prior year.
- Amortizatization of Intangibles slipped to $282000.0 in Q1 2026 per HUMA's latest filing, from $447000.0 in the prior quarter.
- Across five years, Amortizatization of Intangibles topped out at $1.1 million in Q3 2023 and bottomed at -$33000.0 in Q2 2023.
- Historically, Amortizatization of Intangibles has averaged $470058.8 across 5 years, with a median of $517000.0 in 2024.
- On a YoY basis, Amortizatization of Intangibles climbed as much as 25650.0% in 2023 and fell as far as 105.07% in 2023.
- Humacyte's Amortizatization of Intangibles stood at $2000.0 in 2022, then surged by 25650.0% to $515000.0 in 2023, then advanced by 1.55% to $523000.0 in 2024, then declined by 14.53% to $447000.0 in 2025, then plunged by 36.91% to $282000.0 in 2026.
- Business Quant data shows HUMA's Amortizatization of Intangibles at $282000.0 in Q1 2026, $447000.0 in Q4 2025, and $524000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 678,000.00 |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Humacyte | 150.77 Mn | 150.77 Mn | -825,000.00 | 449,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 449,000.00 |
| Jun 30, 2026 | 449,000.00 |
| Mar 31, 2026 | 282,000.00 |
| Mar 31, 2026 | 282,000.00 |
| Dec 31, 2025 | 447,000.00 |
| Dec 31, 2025 | 447,000.00 |
| Sep 30, 2025 | 524,000.00 |
| Sep 30, 2025 | 524,000.00 |
| Jun 30, 2025 | 523,000.00 |
| Jun 30, 2025 | 523,000.00 |
| Mar 31, 2025 | 524,000.00 |
| Mar 31, 2025 | 524,000.00 |
| Dec 31, 2024 | 523,000.00 |
| Dec 31, 2024 | 523,000.00 |
| Sep 30, 2024 | 522,000.00 |
| Sep 30, 2024 | 522,000.00 |
| Jun 30, 2024 | 523,000.00 |
| Jun 30, 2024 | 523,000.00 |
| Mar 31, 2024 | 517,000.00 |
| Mar 31, 2024 | 517,000.00 |